Welcome to Dr. Samanta's Research Group
Research Theme
Antimicrobial resistance (AMR) is rapidly escalating, posing a significant global health challenge. Microbial infections, particularly those caused by multidrug-resistant (MDR) pathogens like the ESKAPE group, are increasingly threatening human health, especially in regions with inadequate antibiotic regulation. Projections suggest that AMR-related deaths could surpass those from cancer by 2050. Biofilm-associated infections further complicate treatment, as cells in biofilm exert nearly thousand fold more resistance to antibiotics as compared to planktonic cells. Addressing this crisis requires novel approaches, such as exploring naturally occurring antimicrobial peptides (AMPs). These short peptides, integral to innate immunity across various organisms, can offer as potent alternatives to traditional antibiotics. Unlike single-target antibiotics, AMPs often have multiple mechanisms of action, reducing the likelihood of resistance development. We aim to indentify the broad-spectrum antibacterial and antibiofilm AMPs against critical priority pathogens like carbapenem resistant Pseudomonas aeruginosa. To achieve our following objectives, we perform both in silico predictions as well as wet laboratory validation in both planktonic and biofilm state of the pathogen.
Research Objectives
1. Identification of naturally occurring AMPs as effective antibacterial, antibiofilm, and anti-inflammatory agents against ESKAPE pathogens.
2. Design and optimization of novel peptides for enhanced antibacterial potency.
3. Database development of manually curated peptides against various pathogens.
In a recent study, we were able to identify potent AMPs released by human microbiome which can target bacterial DNA, leading to cell death.5 After a lot of efforts, we were able to develop databases of manually curated peptides to support research in AMPs.3, 4 In another study, we have shown how peptides containing lysine and arginine repeats can affect the binding of peptides to Beta-lactamases.1 One of our articles works as a guide to screening and selection of suitable AMPs against MDR bacteria.2
References
1. Anurag Anand et al. (2024). International Journal of Peptide Research and Therapeutics. 30, 41. DOI: 10.1007/s10989-024-10619-5.
2. Anurag Anand et al. (2023). Critical Reviews in Microbiology. 1-20. DOI: 10.1080/1040841X.2023.2293019.
3. Mondal et al. (2024). International Journal of Peptide Research and Therapeutics. 30 (36). DOI: 10.1007/s10989-024-10610-0.
4. Mondal et al. (2023). Scientific Reports. 13:17843. DOI: 10.1038/s41598-023-45016-3.
5. Singh et al. (2023). ACS Applied Bio Materials. 6(9), 36743682. DOI: 10.1021/acsabm.3c00302.
Designed & developed by Mr. Rajat Kumar Mondal (M.Tech Bioinformatics 2022-24 Batch) | Last Updated on 6th September, 2024 | Copyright@2024, All Rights Reserved | IIIT-Allahabad, Uttar Pradesh 211 015, India